Skip to content
Subscriber Only
Business
Economics

Stem Cell Showdown: Celltex vs. the FDA

The FDA has put the brakes on a Texas company looking to profit from controversial new therapies
Clockwise from top left, Celltex patients Jennifer Ziegler, Tracy Thompson, Carla Hickman, Preston Walker, Debbie Bertrand, Cecelia Johnson, Sammy Jo Wilkinson, and Bill DeVore
Clockwise from top left, Celltex patients Jennifer Ziegler, Tracy Thompson, Carla Hickman, Preston Walker, Debbie Bertrand, Cecelia Johnson, Sammy Jo Wilkinson, and Bill DeVorePhotographs by Thomas Prior for Bloomberg Businessweek

Cecelia Johnson was an artist, cellist, tap dancer, and 22-year-old college student when she was diagnosed with multiple sclerosis in 2001. The disease, in which the body’s immune system attacks the tissue protecting nerves, proceeds at its own pace: Sometimes the deterioration is halting, sometimes it can be delayed, but there is no cure. Johnson’s decline was swift.

Six years after her diagnosis, undone by fatigue and pain and often unable to walk, Johnson gave up on conventional medicine. In the spring of 2007 she traveled from her home in Houston to Mexico, where an American doctor gave her an infusion of adult stem cells that were supposed to regenerate her damaged tissue. “I thought this guy might be peddling snake oil,” says Johnson. “But I would have taken snake oil.” The procedure cost her $14,000.